Immucell (ICCC) Non-Current Assets (2010 - 2026)
Immucell's (ICCC) quarterly Non-Current Assets came in at $25.6 million in Q4 2025, down 14.87% YoY from $30.1 million in Q4 2024, and down 11.48% on a QoQ basis from $28.9 million in Q3 2025.
Immucell (ICCC) Non-Current Assets (2010 - 2026) Analysis & Trends
Immucell (ICCC) has 16 years of Non-Current Assets data on file, last reported at $25.6 million in Q4 2025.
- Quarterly Non-Current Assets fell 14.87% year-over-year to $25.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $113.8 million (down 7.78% YoY) and the FY2025 annual result came in at $25.6 million, down 14.87% from the prior year.
- Non-Current Assets retreated to $25.6 million in Q4 2025, from $28.9 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $33.1 million in Q2 2023 to a low of $25.6 million in Q4 2025.
- A 5-year average of $29.8 million and a median of $29.8 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets climbed 15.38% — and 2025, when it declined 14.87%.
- Tracing ICCC's Non-Current Assets over 5 years: stood at $28.2 million in 2021, then rose by 9.45% to $30.9 million in 2022, then gained by 4.77% to $32.3 million in 2023, then dropped by 7.05% to $30.1 million in 2024, then dropped by 14.87% to $25.6 million in 2025.
- The last three Non-Current Assets figures came in at $25.6 million (Q4 2025), $28.9 million (Q3 2025), and $29.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Immucell | 92.01 Mn | 83.15 Mn | 2.44 Mn | 25.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.55 Mn |
| Dec 31, 2025 | 25.59 Mn |
| Sep 30, 2025 | 28.90 Mn |
| Jun 30, 2025 | 29.58 Mn |
| Mar 31, 2025 | 29.70 Mn |
| Dec 31, 2024 | 30.06 Mn |
| Sep 30, 2024 | 30.56 Mn |
| Jun 30, 2024 | 31.06 Mn |
| Mar 31, 2024 | 31.70 Mn |
| Dec 31, 2023 | 32.34 Mn |
| Sep 30, 2023 | 32.58 Mn |
| Jun 30, 2023 | 33.06 Mn |
| Mar 31, 2023 | 30.87 Mn |
| Dec 31, 2022 | 30.87 Mn |
| Sep 30, 2022 | 29.97 Mn |
| Jun 30, 2022 | 28.66 Mn |
| Mar 31, 2022 | 28.40 Mn |
| Dec 31, 2021 | 28.20 Mn |
| Sep 30, 2021 | 28.16 Mn |
| Jun 30, 2021 | 28.20 Mn |